By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Accurexa 

1990 North California Boulevard

Walnut Creek  California  94596  U.S.A.
Phone: 302-709-1822 Fax: n/a


SEARCH JOBS

Accurexa is a biotechnology company focused on developing novel neurological therapies to be directly delivered into specific regions of the brain. We are developing our ACX-31 program to deliver two chemotherapy drugs, temozolomide in combination with BCNU, locally to brain tumor sites. Our ACX-31 program is based on an issued patent licensed from Accelerating Combination Therapies LLC which is co-owned by Prof. Henry Brem, Director of the Neurosurgery Department at Johns Hopkins University. We are collaborating in the development of our ACX-31 program with Prof. Henry Brem who built one of the largest brain tumor research and treatment centers in the world at Johns Hopkins University. Prof. Robert Langer, who is the David H. Koch Institute Professor at MIT and the most cited engineer in history, is also advising us in the development of our ACX-31 program. We engaged the Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. ("Yissum") to develop and supply polymeric formulations of a combination of temozolomide and BCNU. Professor Avi Domb leads the development efforts provided by Yissum. Prof. Brem, Prof. Langer and Prof. Domb are pioneers in the development of local drug delivery treatments, and invented and developed GliadelĀ® (carmustine implant) which is a FDA approved, local chemotherapy for the treatment of glioblastoma multiforme.

YEAR FOUNDED:

2012

LEADERSHIP:

Founder and CEO: George Yu

CLINICAL TRIAL:

Please click here for clinical trial information.

PRODUCTS:

BranchPoint Device


Key Statistics


Email:
Ownership: Private

Web Site: Accurexa
Employees:
Symbol: 
 



Industry
Medical Device






Company News
//-->